Azitra vs Lyell Immunopharma
Azitra and Lyell Immunopharma are similar in size: $0 and $36,000 of revenue in their latest fiscal years. Lyell Immunopharma grew faster (-41.0% against -100.0%). Azitra carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AzitraAZTR, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $0 | $36,000 |
| Revenue growth | -100.0% | -41.0% |
| Net income | −$11.0m | −$274m |
| Operating margin | — | -748344.4% |
| Net margin | — | -762355.6% |
| Return on equity | — | -87.0% |
| Free cash flow | −$11.2m | −$151m |
| Cash | $2.1m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 13 | 161 |
| Market value | $53.9m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |